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Demographics of the United States are chang-
ing rapidly. By 2030, the number of individu-
als older than 65 will more than double to
71.5 million [U.S. Administration on Aging
(U.S. AoA) 2004]; one of every ﬁve Americans
will be older than 65 [U.S. Department of
Commerce (U.S. DoC) 1996]. This growth in
the number of older Americans has major
implications from both human and ecologic
health perspectives. For human health, there
will be an increasing need to understand the
impact that environmental exposures and con-
ditions might have on individuals as they
enter later stages of life. Equally important
will be the need to understand the implica-
tions for, or impact on, ecologic resources
associated with accommodating the residen-
tial, medical, recreational, and transportation
needs of this population. This document pre-
sents a preliminary framework for research to
assist the U.S. Environmental Protection
Agency (EPA) to better a) delineate the special
susceptibilities associated with the aged com-
pared with the healthy younger adult popula-
tion, b) identify gaps in knowledge, and
c) provide a starting point to establish research
priorities. Given that the impact of the transi-
tion of “baby boomers” into senior citizens will
rapidly accelerate in the next 5–10 years,
opportunities exist to conduct research in the
interim that will help to better inform decisions
made by policy makers, institutions, and indi-
vidual citizens. For the U.S. EPA, this work
will provide a scientiﬁc rationale for decisions
on how to appropriately incorporate the differ-
ential sensitivity of aging adults into environ-
mental risk assessment, decisions, and actions.
A parallel framework for considering the eco-
logic and resource use implications of the
growing population of older adults is also
being developed (U.S. EPA 2005b).
This article is a brief review based on pri-
mary and secondary sources that address the
susceptibility of older adults to effects of envi-
ronmental exposures and describes a wide
array of research priorities. Two U.S. EPA-
sponsored activities have also greatly
informed this document. The first was the
workshop “Differential Susceptibility and
Exposure of Older Persons to Environmental
Hazards’’ convened by the National Academy
of Sciences (NAS) in December 2002 (NAS
2003). In addition, the U.S. EPA invited
public comments on environmental hazards
that may affect the health of older adults in
states and local communities at six public lis-
tening sessions held throughout the United
States in the spring of 2003 (U.S. EPA
2003a) and from comments sent directly to
the U.S. EPA (2005a). The priorities that
emerged from the NAS workshop and the
public listening sessions were similar to those
previously described by the NAS and the
International Programme on Chemical Safety
(IPCS) (Baker and Rogul 1987; IPCS 1993;
National Research Council 1987).
Environmental Public Health
Framework
A research program focused on the aging
population is consistent with the priority that
the U.S. EPA gives to susceptible subpopula-
tions in its risk assessment/risk management
processes. Several of the U.S. EPA’s statutes
mandate such considerations [e.g., Clean Air
Act of 1970 (1970), Food Quality Protection
Act of 1996 (1996), Safe Drinking Water Act
of 1974 (1974)]. As with the Agency’s well-
established programs to assess risk to children
(U.S. EPA 2000), a program focused on the
aging population must consider factors that
affect susceptibility associated with various life
stages. For example, parallel assumptions are
that individuals may be at greater risk at cer-
tain life stages as a result of modiﬁed pharma-
cokinetic and pharmacodynamic capacity and
different exposure conditions. Susceptibility of
older adults can be defined by qualitative or
quantitative differences. Qualitative differences
mean that exposure-related adverse health out-
comes are present in older adults that are not
present in younger individuals. Quantitative
differences mean that a toxicologic outcome
may be observed at lower doses, have a greater
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The rapid growth in the number of older Americans has many implications for public health, includ-
ing the need to better understand the risks posed to older adults by environmental exposures. Biologic
capacity declines with normal aging; this may be exacerbated in individuals with pre-existing health
conditions. This decline can result in compromised pharmacokinetic and pharmacodynamic responses
to environmental exposures encountered in daily activities. In recognition of this issue, the U.S.
Environmental Protection Agency (EPA) is developing a research agenda on the environment and
older adults. The U.S. EPA proposes to apply an environmental public health paradigm to better
understand the relationships between external pollution sources → human exposures → internal dose
→ early biologic effect → adverse health effects for older adults. The initial challenge will be using
information about aging-related changes in exposure, pharmacokinetic, and pharmacodynamic factors
to identify susceptible subgroups within the diverse population of older adults. These changes may
interact with speciﬁc diseases of aging or medications used to treat these conditions. Constructs such
as “frailty” may help to capture some of the diversity in the older adult population. Data are needed
regarding a) behavior/activity patterns and exposure to the pollutants in the microenvironments of
older adults; b) changes in absorption, distribution, metabolism, and excretion with aging; c) altera-
tions in reserve capacity that alter the body’s ability to compensate for the effects of environmental
exposures; and d) strategies for effective communication of risk and risk reduction methods to older
individuals and communities. This article summarizes the U.S. EPA’s development of a framework to
address and prioritize the exposure, health effects, and risk communications concerns for the U.S.
EPA’s evolving research program on older adults as a susceptible subpopulation. Key words: aging,
environmental health, exposure, frailty, microenvironment, older adults, pharmacodynamics, pharma-
cokinetics, polypharmacy. Environ Health Perspect 113:1257–1262 (2005). doi:10.1289/ehp.7569
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older individuals than in young adults.
It is important to recognize that variability
is a hallmark of the aging population (National
Research Council 1987; Schmucker 1998,
2001; Vestal 1989), so it is likely that members
of an aging population will exhibit variability
in their responses to environmental agents.
Thus, it follows that research will not generate
a “one-size-ﬁts-all” set of recommendations for
risk management/health prevention actions.
For example, at least three subpopulations can
be identiﬁed: a) healthy individuals with nor-
mal but possibly diminishing capacities;
b) individuals confronted with the emergence
of disease/illness associated with later years
(e.g., Alzheimer disease, age-related sensory
losses); and c) individuals already afflicted
with disease/illness entering this period of life
(e.g., cardiovascular disease, respiratory dis-
ease, thyroid deﬁciency, diabetes).
One construct that may account for some
of the variability of the aging population is that
of the “ﬁt” versus “frail” elderly (Crome 2003;
O’Mahoney 2000). Fit refers to older individu-
als who are able to independently perform the
daily activities in the community; frailty refers
to older adults who may not be independently
mobile and may be dependent on others to
carry out daily activities, and are often in insti-
tutionalized care. The roots of frailty may lie in
alterations to multiple physiologic systems
(Walston 2004). It connotes diminished reserve
capacity, diminished resistance to stressors, and
increased health risk (Bortz 2002; Fried et al.
2001; Schuurmans et al. 2004). This construct
may work to summarize the overall effects of
the many conditions that affect health in the
elderly because frailty has been shown to reduce
both pharmacokinetic and pharmacodynamic
functions (Kinirons and O’Mahoney 2004;
Walston et al. 2002). It may also help to
identify individuals or subgroups among the
heterogeneous older adult population that
might be susceptible to environmental agents
because it has been shown to be a better predic-
tor of adverse outcomes in older adults than
chronologic age (Schuurmans et al. 2004).
Additional factors, including sex, socio-
economic status, cultural differences, lifestyle,
nutrition, exposure history, and geographicloca-
tion, may also be used to stratify or characterize
the population of older adults. These sources of
variability can be considered cross-cutting inﬂu-
ences because they may be important determi-
nants of the exposures experienced as well as the
health outcomes. For example, these factors
may modify the environmental exposure
experienced by older individuals through
effects on behavior and lifestyle choices, by
influencing residential choices, daily habits,
and activity patterns. They can also affect how
the body responds to potentially threatening
environmental exposures, influencing both
what the body does to environmental toxicants
(pharmacokinetics) and what those toxicants do
to the body (pharmacodynamics) (Figure 1).
These cross-cutting factors are potential
mediators of susceptibility, some of which are
more the province of other federal agencies.
One goal of this research framework is that it
will be a basis for fostering collaborative
research with these sister agencies.
An environmental public health continuum
(Figure 2) that has been used previously by the
U.S. EPA (2003b, 2003c) to aid in the devel-
opment of broad research strategies has also
been used in this article. Along this continuum
are the cascade of events beginning with the
source through adverse health effects. Research
is directed to helping researchers understand
the determinants inﬂuencing each component
along the continuum and, equally important,
the predictive linkages between components.
The continuum is also of heuristic value in
arraying ongoing research and identifying
major gaps to help set priorities. The following
sections concentrate on the contributions of the
components identified as external exposure,
internal dosimetry, and health outcomes (early
biologic effects and the manifestation of dis-
ease) to the potential susceptibility of older
adults. These data, in turn, provide a basis for
risk management and health promotion.
Exposure
Exposure is the contact between an environ-
mental agent and a target. In exposure assess-
ments, exposure is usually quantified as the
product of the concentration of the agent in
environmental media with which an individ-
ual comes in contact (e.g., air, water, food)
and the time the individual is in contact with
the environmental agent. The behaviors that
bring an individual into contact with an envi-
ronmental agent are important determinants
of the level of exposure. For example, inhala-
tion exposures depend on the microenviron-
ments where people spend their time. The
term “microenvironment” refers to the imme-
diate surroundings of an individual that can
be treated as homogeneous or well character-
ized in the concentrations of an agent (e.g.,
home, office, automobile, kitchen, store).
Understanding microenvironments is critical
because the highest personal exposures may
occur where little time is spent but contami-
nant levels are high. For example, up to 35%
of an individual’s daily exposure to particulate
matter (PM) may come from microenviron-
ments where only 4–13% of time is spent
(Rea et al. 2001). Recent data have been pub-
lished on the personal exposures of older
adults to PM (Lippman et al. 2003; Rodes
et al. 2001; Williams and Wallace 2002).
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Figure 2. Environmental public health continuum used by the U.S. EPA for strategic planning of research.
Modiﬁed from the U.S. EPA (2003c).The sources and pathways of exposure as
well as exposure locations may differ in older
adults compared with younger adults. Current
characterizations of the older adult population
suggest that older adults spend more time
indoors than younger adults, particularly in
residences, and show marked similarities to
the very young (0–4 years of age) in where
they spend their time and in their types of
environmental exposures (Jenkins et al. 1992;
Klepeis et al. 1996; Williams et al. 2000a,
2000b). Time spent indoors is important
because many hazardous air pollutants occur
at higher concentrations indoors, thus poten-
tially exacerbating exposure to indoor air pol-
lutants (Kinney et al. 2002; Saarela et al.
2003; Spengler et al. 1985; U.S. EPA 1998).
There are, however, differences within the
older population, again demonstrating that
this is a heterogeneous group. For example,
older adults in similar residential situations in
different locations (Baltimore, Maryland vs.
Fresno, California) spend different amounts of
time indoors (Rea et al. 2001). Differences in
activity patterns such as cooking, which may
have implications for PM exposure, can also
be seen between older adults in residential
retirement centers (Williams et al. 2000b) and
the broader population (Klepeis et al. 1996).
Dose
The goal of research on internal dosimetry is to
understand the effects of physiologic and bio-
chemical changes with age on target tissue dose
for a given exposure. This work focuses on the
pharmacokinetic processes of absorption,
distribution, metabolism, and elimination
(ADME) that determine the dose of an
environmental agent that reaches a target
organ. Many age-related differences in drug
and toxicant responsiveness appear to be based
on altered ADME (Table 1) (Birnbaum 1991;
Clewell et al. 2002, 2004; Mayersohn 1994;
O’Mahoney 2000; von Moltke et al. 1995).
Changes in these processes mean that the same
external dose may result in a very different
internal dose or distribution to different target
organs in older adults.
The current pharmaceutical literature indi-
cates that ﬁt older adults are quite similar to ﬁt
younger adults in pharmacokinetic parameters,
with the general exceptions of decreased renal
excretion and hepatic processing, secondary to
changes in hepatic blood ﬂow and liver volume
(O’Mahoney 2000). It is notable, however,
that pharmacokinetic function is decreased in
frail older individuals. Disease, physical
trauma, and changes in nutritional status
(O’Mahoney 2000; Walston 2004) can alter
many pharmacokinetic factors (Figure 3).
Absorption. Absorption occurs principally
via the gastrointestinal tract, the respiratory
tract, or the skin. There are no marked age-
related changes in gut absorption after oral
exposure. One exception involves decreased
acid production in the stomach, which
reduces the dissolution of basic compounds
(Mayersohn 1994; O’Mahoney 2000;
Schmucker 1985). The inhalation pathway
may show changes in absorption or deposition
due to age- or disease-related changes in lung
volume, ventilation rate, and alveolar elasticity
(Clewell et al. 2002; Lippman et al. 2003).
For example, changes due to airway obstruc-
tion that accompany chronic obstructive pul-
monary disease result in deeper penetration of
PM and a higher rate of particle deposition
(Brown et al. 2002; Kim and Kang 1997).
Changes in dermal structure and function
with aging may alter dermal absorption such
that the ability of the skin to exclude certain
compounds may be reduced with aging. This
reduction in barrier function is most likely to
accompany pre-existing conditions that place
the skin under stress—the skin of older adults
recovers from stresses signiﬁcantly more slowly
compared with that of younger adults (Elias
and Ghadially 2002; Ghadially et al. 1995; Ye
et al. 2002).
Distribution. Distribution of a chemical
throughout the body can be affected by many
factors, including body composition, blood
flow, and plasma binding proteins (Clewell
et al. 2002). Changes in body composition
(Table 1) can result in reduced volume of
distribution or increased half-lives for xenobiotic
compounds, depending on whether compounds
are soluble in lipids or water (O’Mahoney
2000; Schmucker 1985; von Moltke et al.
1995). Changes in plasma protein binding may
also be critical (Table 1) because the main fac-
tor determining the effect of a compound in the
body is the free, unbound fraction of that com-
pound (Birnbaum 1991; O’Mahoney 2000;
von Moltke et al. 1995). Age-related reductions
in serum albumin can increase the serum-free
fraction of lipophilic compounds, whereas age-
or disease-related increases in α1-acid glyco-
protein affect the binding of basic compounds
(Clewell et al. 2002).
Another potential area of concern is
changes in the blood–brain barrier with aging,
resulting in increased permeability of the cere-
bral microvasculature to toxicants that could
result in neurodegenerative disease. Most data
currently indicate that there are no signiﬁcant
changes in permeability with normal aging
(Shah and Mooradian 1997). Diseases often
associated with aging, however, such as dia-
betes, hypertension, and cerebral ischemic
events, may compromise this barrier function
(Johansson 1998; Mooradian 1997; Starr et al.
2003; Wisniewski and Lossinsky 2002). This
may be important in understanding the envi-
ronmental etiology of conditions such as
parkinsonism, which has been linked to expo-
sure to some compounds that ordinarily show
limited penetration of the blood–brain barrier
(Brooks et al. 1999; Thiruchelvam et al. 2003).
Metabolism. The liver is the major meta-
bolic organ in the body, and studies show that
levels of liver activity drop with aging (Youssef
and Badr 1999). This decreased activity could
result in slowed detoxiﬁcation of some com-
pounds and reduced excretion rates, which can
result in higher effective circulating levels and
longer half-lives.
Although it was initially thought that the
age-related decrease in metabolism was due to
changes in the activity of liver enzymes, current
Research on environmental health and aging
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Table 1. Pharmacokinetic changes that may contribute to increased susceptibility in older persons.
Process Pharmacokinetic changes in aging adults
Absorption No signiﬁcant changes in gastric absorption; decline in gastric acid production
Changes in dermal absorption, barrier function
Changes in lung volume, elasticity, ventilation rate
Distribution Change in body composition
Decreased total body water in older adults results in decreased volume of distribution/higher 
serum levels for polar compounds
Decreased muscle mass and increased relative adipose levels result in higher accumulation
of lipophilic compounds and slower clearance
Plasma protein binding—decrease in plasma albumin (which bind acidic compounds), increase 
in α1-glycoprotein (bind basic compounds)
Potential for increased permeability of blood–brain barrier with concurrent disease (diabetes, 
hypertension, cerebrovascular ischemia)
Metabolism Reduced liver volume and liver blood ﬂow
Minor effects on phase I and II metabolism in healthy aging
Signiﬁcant metabolic effects in conjunction with frailty/age-associated disease
Decline in speciﬁc cytochrome P450 content
Polypharmacy—interactions of environmental toxicants with therapeutic compounds, herbal 
supplements, and diet due to shared metabolic pathways, and/or induction or inhibition of 
metabolic enzymes and/or transporters
Excretion Reduced renal function
Reduced blood ﬂow
Reduced glomerular ﬁltration
Reduced renal MFO activity, inducibility
Reduced biliary excretion
Reduced pulmonary excretion
MFO, mixed-function oxidase.data indicate that most age-related changes in
hepatic activity are due to declines in liver vol-
ume and blood flow with age (O’Mahoney
2000; Schmucker 2001; Vestal 1989). There
are few known signiﬁcant changes in the levels
of activity of metabolic enzymes with normal
aging (Schmucker 1998, 2001; Shimada et al.
1994), but many gaps still remain in the
understanding of aging-related metabolic
changes (Clewell et al. 2002). The disposition
of xenobiotics is also affected by transporters
such as P-glycoprotein (Pgp) and multidrug-
resistance–associated protein. There is increased
Pgp expression in lymphocytes of older adults;
it has been suggested that this may have an
effect on metabolism and drug interactions
(Gupta 1995; Kinirons and O’Mahoney 2004;
McLean and LeCouteur 2004). The effect of
aging on Pgp function throughout the body is
still unknown.
The role of the liver enzymes is critical to
another aspect of the issue of age-related
changes in metabolism: polypharmacy, the
administration of two or more pharmaceutical
compounds to an individual. Studies show that
90% of people older than 65 take one or more
medications daily, with most taking two or
more, and residents of nursing homes or care
facilities average six to eight medications per
individual (Prybys et al. 2002; Vestal 1997).
Because the same biologic processes “clear”
medications and environmental toxicants, there
is concern that older adults who take multiple
medications may be at increased risk of adverse
reactions between medications and concurrent
or subsequent environmental exposures. Either
induction or inhibition of metabolic enzymes
by environmental chemicals (Borlakoglu and
Haegele 1991; Butler and Murray 1997;
Thummel and Wilkinson 1998; Youssef and
Badr 1999) could alter the body’s critical pro-
cessing of pharmacologic agents (Shimada et al.
1994; Thummel and Wilkinson 1998).
Conversely, metabolic processes can make some
environmental chemicals more biologically
active, as in the case of some carcinogens or pes-
ticides (Buratti et al. 2003; Guengerich and
Shimada 1991; Sams et al. 2000). Therefore,
exposure to these compounds, in conjunction
with medications that may induce higher levels
of enzyme activity, could result in greater toxic-
ity (U.S. Food and Drug Administration
2002). Polypharmacy may also affect plasma
protein binding if competitive displacements
occur (Herrlinger and Klotz 2001; Mayersohn
1994; Rolan 1994).
Elimination. The elimination of toxicants
and their metabolites is affected by age-related
changes in hepatic function, described above,
and by decreased kidney function. A decrease
in the rate of renal clearance results in an
increase in the elimination half-life of a com-
pound. Renal changes observed with age
include a decrease in mass of the kidneys, a
reduction in the size and number of nephrons,
a decrease in renal blood ﬂow, and reductions
in glomerular ﬁltration rate, renal plasma ﬂow,
and tubular function (Mayersohn 1994;
O’Mahoney 2000). In addition, the alterations
in pulmonary function that affect absorption
of gases and volatile compounds also will affect
their excretion through the pulmonary route
(Birnbaum 1991). There is also evidence that
bile ﬂow and biliary transport is reduced with
aging, thus reducing excretion through that
route (Birnbaum 1991).
Health Outcomes
There are clear examples of increased health risk
associated with environmental exposures of
older individuals. Research on PM has shown
significant associations between cardio-
pulmonary morbidity and pollutant levels
(Bateson and Schwartz 2004; Zanobetti et al.
2000). Older adults are also more vulnerable to
gastrointestinal disease from waterborne
pathogens (Naumova et al. 2003). However,
aging-related changes in pharmacodynamic
processes that may limit the body’s ability to
maintain homeostasis and respond to injury
have been studied less extensively than the
pharmacokinetic changes (Vestal 1997). Older
adults may be more susceptible to toxicants in
the environment because they have a decreased
ability to compensate for the effects of environ-
mental insult, that is, a reduced “reserve capac-
ity.” The mechanisms underlying a decreased
compensatory ability may be similar across
organ systems but may be expressed differently
in those organ systems. For example, the same
processes that play a major role in cancer initia-
tion and promotion may also play an important
role in cognitive decline with aging (Lu et al.
2004). These processes include DNA damage
in promotor regions of genes with reduced
expression and a reduction in base-excision
DNA repair associated with oxidative stress and
impaired mitochondrial function. Additional
pharmacodynamic changes include age-related
changes in receptor numbers, sensitivity, and
up- and down-regulation, as well as altered sig-
nal transduction, reduced numbers of neurons,
and changes in calcium homeostasis (Goldman
et al. 1994; Michalek et al. 1990). Alterations
to other mechanisms of plasticity or homeostasis
Geller and Zenick
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Figure 3. Predictive modeling to identify the pharmacokinetic parameters that most affect outcomes such as tissue dosimetry and toxicity will consider prototype
toxicants chosen according to a set of criteria (left), physiologic compartments and processes (center), and additional sources of variability that affect physio-
logic function (right). GI, gastrointestinal. All of these contribute to the determination of the level of a toxicant at its biologic target. Shaded boxes indicate which
of the body’s compartments are mainly involved in ADME of environmental exposures, recognizing that almost all tissues have some metabolic capacity. include reduced immune response, altered
response to oxidative stress (Kodavanti 1999),
and reduced DNA repair and anti-proliferation
mechanisms (Frohman 1994; Lu et al. 2004;
Rehman and Masson 2001). Aging also results
in changes in neuroendocrine and neurotrans-
mitter levels (dopamine, GABA, glutamate)
along with alterations in the thyroid–pituitary
axis; decreases in the production of sex steroids,
growth hormone, and insulin-like growth fac-
tor; and increases in glucocorticoids and
cytokines (Frohman 1994; Rehman and
Masson 2001 Smith et al. 2004). These age-
related alterations in function may then con-
tribute to the increased vulnerability of older
individuals to a variety of environmentally
linked adverse health outcomes. Examples
include neurotoxicity (Kodavanti 1999;
Spencer 1990; Weiss 1990), cancer (Akman
2003), cardiovascular and pulmonary morbid-
ity (Lippman et al. 2003; Reaven 2003),
inﬂammatory responses (McCord 2003), and
gastrointestinal effects associated with increased
susceptibility to waterborne pathogens
(Naumova et al. 2003).
Research Recommendations
One of the challenges in conducting research
on aging is addressing the great diversity of
health and exposure conditions of the older
adult population. To be responsive to public
health needs, it is important to be able to pre-
dict which older adults, deﬁned not only by age
but also by the inﬂuence of the cross-cutting
factors discussed above, will be most susceptible
and to which environmental agents. Employing
the environmental public health continuum
(Figure 2), the following are research areas
under initial consideration by U.S. EPA.
Exposure: provide data for use in source-to-
dose exposure models applicable to older adult
populations and information speciﬁc to older
adults for the U.S. EPA Exposure Factors
Handbook (U.S. EPA 1997). Initial steps
include the identification of susceptible sub-
groups of older adults on the basis of exposure
and activity modeling. Exposure models will be
derived from information on chemical and
biologic stressors, geographic location, and
health status drawn from existing databases at
the U.S. EPA. Other resources to be “mined”
include age-specific census, occupational,
dietary, and product safety data. Research on
activity patterns and microenvironments of
importance to the elder population includes
characterization of time spent indoors, recre-
ational choices, occupation, control over the
environment in group housing, and the effects
of reduced mobility, lifestyle choices, and isola-
tion. This initial modeling and compilation of
data will help researchers identify and prioritize
data gaps. This will, in turn, generate hypothe-
ses and guide further development of the data-
base and reﬁnement of models for assessing the
degree to which susceptibility in older adults is
due to differences between older and younger
adults in activity and in exposures to harmful
environmental agents.
Dose: determine the contribution of age-
related alterations in pharmacokinetics to the
susceptibility of older adults. The initial steps in
this research will also be model-driven in that
sensitivity analysis will help to determine which
factors, such as changes in particular metabolic
enzymes, transport processes, or excretion func-
tions, are most important for particular classes
of chemicals. Modeling should also deﬁne the
magnitude of change necessary for a factor to
alter the exposure–dose–response relationship
for prototype chemicals. This will help to nar-
row the focus for empirical research on physio-
logic and biochemical parameters that will have
the greatest effect in older adults by overlaying
those factors on the ones that are known to
change with aging and with diseases of aging. It
may also help to deﬁne which diseases or medi-
cations might be expected to increase suscepti-
bility to effects of environmental exposures
(Figure 3). Susceptibility due to pharmaceutical
use will be informed by our understanding of
the common mechanisms underlying the
metabolism of pharmaceutical compounds and
environmental agents. In addition, identiﬁca-
tion of critical kinetic factors will aid in the
evaluation and development of animal or
in vitro models because effects noted in rodent
models of aging have not always accurately
reﬂected changes present in aging humans (e.g.,
Schmucker 2001).
Health outcomes: determine the relation-
ship between exposure to environmental agents
and adverse health effects in aging populations.
Data from mechanistic research conducted to
understand the age-dependence of pharmaco-
dynamic processes such as protective, repair,
compensatory, and plasticity mechanisms
across organ systems can be applied to the
question of whether mode of action informa-
tion can predict which subpopulations are sus-
ceptible to the effects of environmental agents.
As with the pharmacokinetic approach, this
work will identify and prioritize the processes
or mechanisms that confer susceptibility on
aging adults and match these with environ-
mental agents presumed to operate through
similar putative mechanisms.
Risk communication: develop a strategy for
communication of risk, risk management, and
public health intervention. This will likely
include the dissemination of information to
and through environmental and health profes-
sionals, state and local governments, developers
of senior communities, and the broad commu-
nity of professionals, organizations, and associ-
ations involved with aging issues. Effective
communication must consider the social and
cognitive strategies most appropriate for older
adults (Helmuth 2003; Park 2002).
Conclusion
The research framework we describe in this
article focuses on the potential for interactions
between aging and environmental exposures to
produce adverse health effects in older adults.
This research program will generate data on
exposures that the aging population experi-
ences and the subsequent pharmacokinetic and
target organ responses, with the goal of pro-
viding a better understanding of the environ-
mental health risks associated with aging in
healthy or compromised older adults. These
data will be used to generate models and guid-
ance on how to appropriately incorporate the
differential susceptibility of this heterogeneous
subpopulation into health promotion and
intervention strategies to ameliorate risk from
environmental exposures.
Now, still a few years away from the crest-
ing of this demographic wave, is the time to
anticipate, accommodate, and manage the
environmental risks associated with this
inevitable shift in American demographics
toward an aging society.
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